NCT03504488: CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors

NCT03504488
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Only TNBC patients are eligible for the expansion phase
Exclusions: Patients with known uncontrolled CNS metastasis
https://ClinicalTrials.gov/show/NCT03504488

Comments are closed.

Up ↑